Bridge crossed by HeartWare
Tuesday, 23 September, 2008
The US FDA has approved the left ventricular assist system [LVAS] developed by HeartWare [ASX: HTW] for an Investigational Device Exemption (IDE).
The company is now clear to conduct clinical trials of the device, which are to be held at the Washington Hospital Centre, with one patient already enrolled.
The trial is a bridge-to-transplant trial in patients with end-stage heart failure.
HeartWare is in the process of finalising contractual arrangements at a number of additional centres. Seven centres so far have been trained in the use of the product.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
